Prothena Corporation PLC (NASDAQ:PRTA) received a $73.00 price objective from equities researchers at Deutsche Bank AG in a research report issued on Monday. The brokerage presently has a “buy” rating on the biotechnology company’s stock. Deutsche Bank AG’s price objective indicates a potential upside of 25.97% from the company’s previous close.

Other equities research analysts also recently issued research reports about the company. Royal Bank Of Canada assumed coverage on Prothena Corporation PLC in a report on Thursday, September 14th. They set an “outperform” rating and a $87.00 price target for the company. BidaskClub downgraded Prothena Corporation PLC from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Jefferies Group LLC assumed coverage on Prothena Corporation PLC in a report on Monday, July 10th. They set a “buy” rating and a $100.00 price target for the company. Cantor Fitzgerald reaffirmed a “buy” rating and set a $79.00 price target on shares of Prothena Corporation PLC in a report on Thursday, September 28th. Finally, ValuEngine raised Prothena Corporation PLC from a “sell” rating to a “hold” rating in a report on Friday, September 1st. One analyst has rated the stock with a sell rating and fourteen have assigned a buy rating to the stock. Prothena Corporation PLC currently has a consensus rating of “Buy” and an average target price of $78.58.

Shares of Prothena Corporation PLC (PRTA) traded up 0.07% during trading on Monday, reaching $57.95. 175,612 shares of the company were exchanged. The company has a 50 day moving average price of $62.53 and a 200-day moving average price of $57.85. The stock’s market capitalization is $2.22 billion. Prothena Corporation PLC has a one year low of $40.58 and a one year high of $70.00.

Prothena Corporation PLC (NASDAQ:PRTA) last released its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.89) by $0.43. The company had revenue of $26.81 million during the quarter, compared to the consensus estimate of $16.08 million. Prothena Corporation PLC had a negative return on equity of 33.20% and a negative net margin of 527.56%. The firm’s revenue for the quarter was up 7951.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.18) EPS. Equities analysts predict that Prothena Corporation PLC will post ($4.41) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This story was posted by American Banking News and is the property of of American Banking News. If you are reading this story on another website, it was illegally copied and republished in violation of US and international copyright and trademark laws. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/10/23/deutsche-bank-ag-reiterates-73-00-price-target-for-prothena-corporation-plc-prta.html.

In other Prothena Corporation PLC news, Director Christopher S. Henney sold 900 shares of the stock in a transaction on Thursday, September 28th. The stock was sold at an average price of $70.00, for a total transaction of $63,000.00. Following the transaction, the director now owns 900 shares in the company, valued at approximately $63,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Tara Nickerson sold 17,500 shares of the stock in a transaction on Monday, September 25th. The stock was sold at an average price of $63.60, for a total value of $1,113,000.00. Following the transaction, the insider now owns 19,500 shares in the company, valued at approximately $1,240,200. The disclosure for this sale can be found here. Insiders have sold a total of 29,424 shares of company stock valued at $1,922,787 in the last ninety days. Insiders own 3.10% of the company’s stock.

A number of hedge funds have recently bought and sold shares of the business. Woodford Investment Management Ltd increased its position in Prothena Corporation PLC by 2.6% during the 2nd quarter. Woodford Investment Management Ltd now owns 11,400,424 shares of the biotechnology company’s stock worth $616,991,000 after buying an additional 294,213 shares during the period. FMR LLC increased its position in Prothena Corporation PLC by 0.7% during the 2nd quarter. FMR LLC now owns 5,699,234 shares of the biotechnology company’s stock worth $308,443,000 after buying an additional 39,926 shares during the period. BlackRock Inc. increased its position in Prothena Corporation PLC by 7.8% during the 2nd quarter. BlackRock Inc. now owns 2,947,512 shares of the biotechnology company’s stock worth $159,519,000 after buying an additional 213,578 shares during the period. State Street Corp increased its position in Prothena Corporation PLC by 10.6% during the 2nd quarter. State Street Corp now owns 1,181,365 shares of the biotechnology company’s stock worth $63,932,000 after buying an additional 113,193 shares during the period. Finally, Palo Alto Investors LLC increased its position in Prothena Corporation PLC by 1.7% during the 2nd quarter. Palo Alto Investors LLC now owns 1,073,955 shares of the biotechnology company’s stock worth $58,122,000 after buying an additional 18,100 shares during the period.

About Prothena Corporation PLC

Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).

Analyst Recommendations for Prothena Corporation PLC (NASDAQ:PRTA)

Receive News & Ratings for Prothena Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena Corporation PLC and related companies with MarketBeat.com's FREE daily email newsletter.